MCID: BSL007
MIFTS: 64

Basal Cell Carcinoma

Categories: Cancer diseases, Skin diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Basal Cell Carcinoma

MalaCards integrated aliases for Basal Cell Carcinoma:

Name: Basal Cell Carcinoma 12 29 14 69
Basal Cell Cancer 12 52 69
Malignant Basal Cell Tumor 12 69
Basal Cell Neoplasm 12 69
Experimental Organism Basal Cell Carcinoma 69
Nodulo-Ulcerative Basal Cell Carcinoma 69
Malignant Basal Cell Neoplasm 12
Basal Cell Carcinoma of Skin 12
Basal Cell Carcinoma Nos 12
Basal Cell Neoplasm Nos 12
Epithelioma Basal Cell 12
Carcinoma, Basal Cell 42
Neoplasms, Basal Cell 42
Carcinoma Basal Cell 52
Basal Cell Tumor 12
Rodent Ulcer 12

Classifications:



Summaries for Basal Cell Carcinoma

Disease Ontology : 12 A skin carcinoma affecting basal cells.

MalaCards based summary : Basal Cell Carcinoma, also known as basal cell cancer, is related to pigmented basal cell carcinoma and basal cell carcinoma 1. An important gene associated with Basal Cell Carcinoma is SMO (Smoothened, Frizzled Class Receptor), and among its related pathways/superpathways are Basal cell carcinoma and Signaling by GPCR. The drugs Erivedge and Intron A have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and kidney, and related phenotypes are cellular and growth/size/body region

Wikipedia : 72 Basal-cell carcinoma (BCC), also known as basal-cell cancer, is the most common type of skin cancer. It... more...

Related Diseases for Basal Cell Carcinoma

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 6
Basal Cell Carcinoma 5 Basal Cell Carcinoma 4
Basal Cell Carcinoma 7 Cell Type Cancer
Cell Type Benign Neoplasm Basal Cell Carcinoma
Large Cell Carcinoma Basal Cell Carcinoma, Multiple

Diseases related to Basal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 261)
id Related Disease Score Top Affiliating Genes
1 pigmented basal cell carcinoma 34.2 KRT17 KRT20 SUFU
2 basal cell carcinoma 1 34.1 PALB2 PTCH1 PTCH2 SMO
3 anal margin basal cell carcinoma 33.9 KRT15 PTCH1 WNT16
4 cystic basal cell carcinoma 33.7 KRT15 KRT17 KRT20
5 follicular basal cell carcinoma 33.6 KRT15 KRT17 KRT20
6 basal cell nevus syndrome 33.4 GLI1 GLI2 GLI3 PTCH1 PTCH2 SHH
7 trichoepithelioma, multiple familial, 1 32.8 CYLD PTCH1 TP53
8 childhood medulloblastoma 30.3 GLI1 PTCH1 SHH SUFU TP53
9 basal cell carcinoma 7 12.2
10 nodular basal cell carcinoma 12.2
11 superficial basal cell carcinoma 12.2
12 infundibulocystic basal cell carcinoma 12.2
13 morpheaform basal cell carcinoma 12.2
14 infiltrative basal cell carcinoma 12.1
15 adenoid basal cell carcinoma 12.1
16 clear cell basal cell carcinoma 12.1
17 metatypical basal cell carcinoma 12.1
18 sarcomatoid basal cell carcinoma 12.1
19 micronodular basal cell carcinoma 12.1
20 fibroepithelial basal cell carcinoma 12.1
21 vulva basal cell carcinoma 12.0
22 basal cell carcinoma, multiple 12.0
23 bazex syndrome 12.0
24 external ear basal cell carcinoma 12.0
25 scrotum basal cell carcinoma 12.0
26 basal cell carcinoma 6 11.9
27 sebaceous basal cell carcinoma 11.9
28 basal cell carcinoma 5 11.9
29 basal cell carcinoma 4 11.9
30 basal cell carcinoma 2 11.9
31 penis basal cell carcinoma 11.9
32 basal cell carcinoma 3 11.9
33 signet ring basal cell carcinoma 11.9
34 rombo syndrome 11.8
35 brooke-spiegler syndrome 11.2
36 multiple familial trichoepithelioma 11.2
37 dermis tumor 10.9 CYLD TP53
38 camptocormism 10.9 GLI2 PTCH1 TP53
39 homocystinuria due to defect in methylation cbl g 10.9 GLI2 PTCH1
40 adamantinoid basal cell epithelioma 10.9
41 eosinophilic granuloma 10.9
42 sporadic pheochromocytoma 10.9 GLI2 PTCH1 SHH
43 celosomia 10.9 GLI2 PTCH1 SHH
44 laryngotracheoesophageal cleft type 2 10.9 GLI2 PTCH1 SHH
45 glycogen storage disease due to lactate dehydrogenase deficiency 10.8 CTNNB1 TP53
46 laryngotracheoesophageal cleft type 4 10.8 GLI2 PTCH1 SHH
47 isolated facial myokymia 10.8 GLI2 PTCH1 SHH
48 xeroderma pigmentosum, variant type 10.8
49 prostate cancer, hereditary, 2 10.8
50 prostate cancer, hereditary, 11 10.8

Graphical network of the top 20 diseases related to Basal Cell Carcinoma:



Diseases related to Basal Cell Carcinoma

Symptoms & Phenotypes for Basal Cell Carcinoma

MGI Mouse Phenotypes related to Basal Cell Carcinoma:

44 (show all 22)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.44 TP53 PALB2 PTCH1 SHH SMO BAX
2 growth/size/body region MP:0005378 10.43 HHIP KRT17 MC1R PALB2 PTCH1 SHH
3 digestive/alimentary MP:0005381 10.4 SMO SUFU TP53 CTNNB1 CYLD GLI1
4 craniofacial MP:0005382 10.37 CTNNB1 GLI1 GLI2 GLI3 HHIP KRT17
5 mortality/aging MP:0010768 10.36 PALB2 PTCH1 SHH SMO SUFU TP53
6 limbs/digits/tail MP:0005371 10.34 MC1R PALB2 PTCH1 SHH SMO SUFU
7 embryo MP:0005380 10.32 CTNNB1 GLI1 GLI2 GLI3 HHIP PALB2
8 integument MP:0010771 10.31 CTNNB1 CYLD GLI2 GLI3 KRT17 MC1R
9 cardiovascular system MP:0005385 10.3 CTNNB1 GLI3 TP53 MMP11 PALB2 PTCH1
10 endocrine/exocrine gland MP:0005379 10.27 BAX CTNNB1 CYLD GLI1 GLI2 GLI3
11 nervous system MP:0003631 10.27 PTCH2 SHH SMO SUFU TP53 BAX
12 neoplasm MP:0002006 10.26 BAX CTNNB1 CYLD GLI1 MC1R MMP11
13 hearing/vestibular/ear MP:0005377 10.15 BAX CTNNB1 GLI2 GLI3 MC1R SHH
14 normal MP:0002873 10.14 CTNNB1 CYLD GLI1 GLI2 GLI3 PTCH1
15 no phenotypic analysis MP:0003012 10.13 CTNNB1 GLI1 GLI2 GLI3 KRT17 MC1R
16 muscle MP:0005369 10.1 PTCH1 PTCH2 SHH SMO TP53 BAX
17 respiratory system MP:0005388 9.93 BAX CTNNB1 CYLD GLI1 GLI2 GLI3
18 pigmentation MP:0001186 9.91 TP53 CTNNB1 GLI3 KRT17 MC1R PTCH1
19 reproductive system MP:0005389 9.91 BAX CTNNB1 GLI1 GLI2 GLI3 PTCH1
20 renal/urinary system MP:0005367 9.87 BAX CTNNB1 GLI1 GLI3 PTCH1 SHH
21 skeleton MP:0005390 9.65 BAX CTNNB1 GLI2 GLI3 PTCH1 SHH
22 vision/eye MP:0005391 9.32 TP53 BAX CTNNB1 GLI2 GLI3 HHIP

Drugs & Therapeutics for Basal Cell Carcinoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Erivedge 17 46 VISMODEGIB Genentech January 2012
2
Intron A 17 46 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
3
Odomzo 17 46 SONIDEGIB PHOSPHATE Novartis Jul-15

Drugs for Basal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 261)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 106-60-5 137
2
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99011-02-6 57469
3
Fluorouracil Approved Phase 4,Phase 2,Phase 1 51-21-8 3385
4
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
5
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 6442177
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 22916-47-8 4189
7
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
8
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
9 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
10 Methyl 5-aminolevulinate Phase 4,Phase 3,Phase 2,Phase 1
11 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
13 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1
14 interferons Phase 4,Phase 3,Phase 2,Phase 1
15 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Antiviral Agents Phase 4,Phase 2,Phase 1
17 Immunosuppressive Agents Phase 4,Phase 2,Phase 1
18 Anti-Bacterial Agents Phase 4,Phase 1,Phase 2
19 Antibiotics, Antitubercular Phase 4,Phase 1,Phase 2
20 Antirheumatic Agents Phase 4,Phase 2
21 Interferon-alpha Phase 4
22 Antimetabolites Phase 4,Phase 2,Phase 1
23 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 1
24 Tin Fluorides Phase 4
25 triamcinolone acetonide Phase 4,Phase 2
26 Triamcinolone diacetate Phase 4,Phase 2
27 Triamcinolone hexacetonide Phase 4,Phase 2
28 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
29 Calcineurin Inhibitors Phase 4
30 Cyclosporins Phase 4
31
Selenium Approved, Vet_approved Phase 3 7782-49-2
32
Zinc Approved Phase 3 7440-66-6 32051 23994
33
Fluconazole Approved Phase 2, Phase 3 86386-73-4 3365
34
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
35
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
36
Megestrol acetate Approved, Vet_approved Phase 3 595-33-5 11683
37
Doxepin Approved Phase 3 1668-19-5 667477 667468
38
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
39
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
40
Verteporfin Approved, Investigational Phase 3 129497-78-5
41
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538
42
Ornithine Approved, Nutraceutical Phase 3,Phase 2 70-26-8, 3184-13-2 6262 389
43
B-Carotene Approved, Nutraceutical Phase 3 7235-40-7 5280489
44 Tocopherol Approved, Nutraceutical Phase 3
45
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
46
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
47 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
48
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
49 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3,Early Phase 1
50 Anesthetics Phase 3,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 290)

id Name Status NCT ID Phase Drugs
1 Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
2 Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma Unknown status NCT00803907 Phase 4 Imiquimod 5% cream
3 Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage Completed NCT00314756 Phase 4 imiquimod
4 Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC) Completed NCT00581425 Phase 4
5 Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma Completed NCT00204555 Phase 4 Imiquimod
6 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
7 Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
8 VISmodegib for ORbital and Periocular Basal Cell Carcinoma Recruiting NCT02436408 Phase 4 Vismodegib
9 Periocular Basal Cell Carcinoma (BCC): Permanent vs. Frozen Section Pathological Control Unknown status NCT00663650 Phase 3
10 Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream Completed NCT00189306 Phase 3 Imiquimod 5% cream
11 Treatment of Primary Basal Cell Carcinomas of the Skin With Combination of Topical Imiquimod and Cryosurgery Completed NCT01212562 Phase 3
12 A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma Completed NCT00189241 Phase 3 imiquimod
13 Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma Completed NCT00472108 Phase 3
14 Metvix PDT Versus Cryotherapy in Patients With Primary Superficial Basal Cell Carcinoma Completed NCT00469417 Phase 3
15 A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence Completed NCT00129519 Phase 3 Imiquimod 5% cream
16 Comparison of Two Schemes of Cryosurgery and Imiquimod Combination Treatment for Basal Cell Carcinoma Completed NCT01212549 Phase 3
17 Metvix PDT in Patients With "High Risk" Basal Cell Carcinoma Completed NCT00473343 Phase 3
18 Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer Completed NCT00066872 Phase 3 imiquimod
19 PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Call Carcinoma Completed NCT00472043 Phase 3
20 Fractional CO2 Laser Assisted Photodynamic Therapy Completed NCT01260987 Phase 2, Phase 3 Conventional photodynamic therapy;Fractional CO2 laser assisted PDT
21 Topical Green Tea Ointment in Treatment of Superficial Skin Cancer Completed NCT02029352 Phase 2, Phase 3 Sinecatechins 10%;Placebo
22 Aldara for the Treatment of Large and/or Multiple sBCC Completed NCT00189280 Phase 3 Imiquimod
23 Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer Completed NCT00007631 Phase 3 Tretinoin 0.1% cream or placebo
24 Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer Completed NCT00005884 Phase 3 eflornithine
25 Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals. Completed NCT00272428 Phase 3
26 PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin Cancer Completed NCT00472459 Phase 3
27 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
28 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
29 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
30 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
31 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
32 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
33 Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma Recruiting NCT02242929 Phase 3 Imiquimod 5% cream with prior curettage
34 Radiotherapy or Imiquimod in Complex Lentigo Maligna Recruiting NCT02394132 Phase 3 Imiquimod
35 Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy Active, not recruiting NCT02144077 Phase 3 BF-200 ALA;methyl-aminolevulinate
36 Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Active, not recruiting NCT01362140 Phase 3 Darbepoetin alfa;Placebo
37 Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin. Terminated NCT00049959 Phase 3 verteporfin PDT
38 Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients Terminated NCT01532453 Phase 3
39 Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) Withdrawn NCT03070691 Phase 2, Phase 3 LDE225B;Vehicle
40 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
41 Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight Unknown status NCT01349361 Phase 2
42 Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Skin Cancer Unknown status NCT00747903 Phase 2 aminolevulinic acid hydrochloride
43 Low Fat Diet to Prevent Disease Progression in Patients With Skin Cancer Unknown status NCT00003097 Phase 2
44 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
45 A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas Completed NCT01815840 Phase 2 Vismodegib;Placebo
46 Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma Completed NCT00108121 Phase 2 PEP005
47 Vismodegib for Treatment of Basal Cell Carcinoma Completed NCT01543581 Phase 2 Vismodegib;Placebo
48 Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas Completed NCT01108094 Phase 2 Itraconazole
49 A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma Completed NCT00833417 Phase 2 Vismodegib 150 mg
50 Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma Completed NCT00108134 Phase 2 PEP005

Search NIH Clinical Center for Basal Cell Carcinoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: carcinoma, basal cell

Genetic Tests for Basal Cell Carcinoma

Genetic tests related to Basal Cell Carcinoma:

id Genetic test Affiliating Genes
1 Basal Cell Carcinoma 29

Anatomical Context for Basal Cell Carcinoma

MalaCards organs/tissues related to Basal Cell Carcinoma:

39
Skin, Lung, Kidney, Brain, Liver, Breast, Testes

Publications for Basal Cell Carcinoma

Articles related to Basal Cell Carcinoma:

(show top 50) (show all 1784)
id Title Authors Year
1
Superficial basal cell carcinoma: Dermoscopic and histopathological features of multiple small erosions. ( 28677117 )
2017
2
Inoperable infiltrative basal cell carcinoma successfully treated with vismodegib. ( 28631369 )
2017
3
Standard step sectioning of skin biopsy specimens diagnosed as superficial basal cell carcinoma frequently yields deeper and more aggressive subtypes. ( 28088999 )
2017
4
A rare dermoscopic pattern of nodular basal cell carcinoma with amyloid deposition. ( 28087032 )
2017
5
Risks of different skin tumor combinations after a first melanoma, squamous cell carcinoma and basal cell carcinoma in Dutch population based cohorts: 1989 - 2009. ( 28898461 )
2017
6
Infundibulocystic basal cell carcinoma of the eyelid. ( 28660686 )
2017
7
Unusual Neurological Presentation of Nevoid Basal Cell Carcinoma Syndrome (Gorlin-Goltz Syndrome). ( 28884983 )
2017
8
Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin. ( 28887802 )
2017
9
Variation in dermoscopic features of basal cell carcinoma as a function of anatomic location and pigmentation status. ( 28886224 )
2017
10
Use of a cotton-tipped applicator for superior clinical diagnosis and biopsy of suspected basal cell carcinoma of the nasal ala. ( 27986150 )
2017
11
Phasor-FLIM as a Screening Tool for the Differential Diagnosis of Actinic Keratosis, Bowen's Disease, and Basal Cell Carcinoma. ( 28661125 )
2017
12
Phaeohyphomycosis of the Face Masquerading as Basal Cell Carcinoma in an Immunocompetent Patient. ( 28761846 )
2017
13
Dynamic Thiol/Disulphide Homeostasis in patients with Basal Cell Carcinoma. ( 28067074 )
2017
14
Superficial basal cell carcinoma treated with 70% trichloroacetic acid applied topically: a case study. ( 28260938 )
2017
15
GREM1 is expressed in the cancer-associated myofibroblasts of basal cell carcinomas. ( 28346486 )
2017
16
A Case of Phacomatosis Pigmentokeratotica Associated With Multiple Basal Cell Carcinomas. ( 28937433 )
2017
17
Methyl aminolevulinate photodynamic therapy combined with curettage debulking for pigmented basal cell carcinoma. ( 28500762 )
2017
18
Hormonal and reproductive factors and incidence of basal cell carcinoma and squamous cell carcinoma in a large, prospective cohort. ( 28947292 )
2017
19
Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5-aminolevulinic acid 20% versus two stage topical methylaminolevulinic acid: results of a randomized controlled trial. ( 28886209 )
2017
20
FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma. ( 28073840 )
2017
21
Photodynamic Therapy Effective for the Treatment of Actinic Keratosis and Basal Cell Carcinoma in Bullous Pemphigoid Patients. ( 28373119 )
2017
22
Simultaneous Development of Three Different Neoplasms of Trichilemmoma, Desmoplastic Trichilemmoma and Basal Cell Carcinoma Arising from Nevus Sebaceus. ( 28913303 )
2017
23
ACTRT1 Inhibits Hedgehog Signaling to Suppress Basal Cell Carcinoma. ( 28916586 )
2017
24
Reactive Eccrine Syringofibroadenoma Associated With Basal Cell Carcinoma: A Histologic Mimicker of Fibroepithelioma of Pinkus. ( 28902033 )
2017
25
The concerted action of type 2 and type 3 deiodinases regulates the cell cycle and survival of basal cell carcinoma cells. ( 28088877 )
2017
26
Topical Sinecatechins, 10%, Ointment for Superficial Basal Cell Carcinoma: A Randomized Clinical Trial. ( 28793140 )
2017
27
Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area. ( 28300740 )
2017
28
Ambulatory Photodynamic Therapy for Superficial Basal Cell Carcinoma: An Effective Light Source? ( 28093601 )
2017
29
Photodynamic therapy with epidermal ablation using fractional CO2 laser for treating superficial basal cell carcinoma: A case series. ( 28647617 )
2017
30
Molecular basis of basal cell carcinoma. ( 28954101 )
2017
31
Evaluation of the Level of Zinc and Malondialdehyde in Basal Cell Carcinoma. ( 28894712 )
2017
32
Multiple Basal Cell Carcinomas in a Patient of Oculocutaneous Albinism. ( 28405556 )
2017
33
Follicular and cystic regression of locally advanced basal cell carcinoma following short-term neoadjuvant vismodegib therapy. ( 28898543 )
2017
34
Association between genetic variation within vitamin D receptor-DNA binding sites and risk of basal cell carcinoma. ( 28177523 )
2017
35
Basal Cell Carcinoma in Erythropoietic Protoporphyria: All About Ultraviolet Light? ( 28903600 )
2017
36
Treatment patterns and outcomes for patients with locally advanced basal cell carcinoma before availability of Hedgehog pathway inhibitors: a retrospective chart review. ( 28862133 )
2017
37
Incidence ratio of basal cell carcinoma to squamous cell carcinoma equalizes with age. ( 28089000 )
2017
38
Polyalkylimide and Invasive Growth of Basal Cell Carcinoma of the Skin. ( 28857938 )
2017
39
Differential BMI1, TWIST1, SNAI2 mRNA expression pattern correlation with malignancy type in a spectrum of common cutaneous malignancies: basal cell carcinoma, squamous cell carcinoma, and melanoma. ( 27718152 )
2017
40
Patient preferences for the attributes of a non-invasive treatment for superficial Basal cell carcinoma: a discrete choice experiment. ( 28667739 )
2017
41
Basal cell carcinoma of the temporal bone and external auditory canal. ( 28850700 )
2017
42
Pulmonary metastases in a patient with an aggressive infiltrative basal cell carcinoma of the scalp. ( 28251897 )
2017
43
Microbiopsy Biomarker Profiling in a Superficial Melanoma Resembling a Pigmented Basal Cell Carcinoma. ( 28196220 )
2017
44
Genetic association between TNF-I+ promoter polymorphism and susceptibility to squamous cell carcinoma, basal cell carcinoma, and melanoma: A meta-analysis. ( 28881857 )
2017
45
Cutaneous Basal Cell Carcinoma Arising in Odontogenic Cutaneous Fistula. ( 28913323 )
2017
46
Superficial basal cell carcinoma: A comparison of superficial only subtype with superficial combined with other subtypes by age, sex and anatomic site in 3150 cases. ( 28493477 )
2017
47
Molecular Variations in Histologic Subtypes of Basal Cell Carcinoma. ( 28859735 )
2017
48
Reflectance confocal microscopy as a noninvasive diagnostic tool for naevoid basal cell carcinoma syndrome management. ( 28044368 )
2017
49
Long-Term Efficacy and Safety of Sonidegib in Patients With Locally Advanced and Metastatic Basal Cell Carcinoma: 30-Month Analysis of the Randomized Phase 2 BOLT Study. ( 28846163 )
2017
50
Dermatofibrosarcoma protuberans post basal cell carcinoma excision: A case report. ( 27494371 )
2016

Variations for Basal Cell Carcinoma

ClinVar genetic disease variations for Basal Cell Carcinoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 PALB2 NM_024675.3(PALB2): c.1451T> A (p.Leu484Ter) single nucleotide variant Pathogenic rs786203714 GRCh38 Chromosome 16, 23635095: 23635095
2 SMO NM_005631.4(SMO): c.1417G> C (p.Asp473His) single nucleotide variant Pathogenic rs17710891 GRCh37 Chromosome 7, 128849189: 128849189

Cosmic variations for Basal Cell Carcinoma:

9 (show top 50) (show all 225)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM44071 TP53 skin,NS,carcinoma,basal cell carcinoma c.955A>G p.K319E 16
2 COSM43635 TP53 skin,NS,carcinoma,basal cell carcinoma c.536A>T p.H179L 16
3 COSM43920 TP53 skin,NS,carcinoma,basal cell carcinoma c.680C>T p.S227F 16
4 COSM43582 TP53 skin,NS,carcinoma,basal cell carcinoma c.454C>T p.P152S 16
5 COSM10650 TP53 skin,NS,carcinoma,basal cell carcinoma c.529C>T p.P177S 16
6 COSM44436 TP53 skin,NS,carcinoma,basal cell carcinoma c.375+2T>C p.? 16
7 COSM10705 TP53 skin,NS,carcinoma,basal cell carcinoma c.586C>T p.R196* 16
8 COSM10812 TP53 skin,NS,carcinoma,basal cell carcinoma c.722C>T p.S241F 16
9 COSM45734 TP53 skin,NS,carcinoma,basal cell carcinoma c.622G>T p.D208Y 16
10 COSM44096 TP53 skin,NS,carcinoma,basal cell carcinoma c.748C>G p.P250A 16
11 COSM43616 TP53 skin,NS,carcinoma,basal cell carcinoma c.704A>G p.N235S 16
12 COSM43596 TP53 skin,NS,carcinoma,basal cell carcinoma c.841G>A p.D281N 16
13 COSM10656 TP53 skin,NS,carcinoma,basal cell carcinoma c.742C>T p.R248W 16
14 COSM44310 TP53 skin,NS,carcinoma,basal cell carcinoma c.738G>A p.M246I 16
15 COSM10654 TP53 skin,NS,carcinoma,basal cell carcinoma c.637C>T p.R213* 16
16 COSM10749 TP53 skin,NS,carcinoma,basal cell carcinoma c.830G>T p.C277F 16
17 COSM11084 TP53 skin,NS,carcinoma,basal cell carcinoma c.517G>A p.V173M 16
18 COSM45138 TP53 skin,NS,carcinoma,basal cell carcinoma c.853G>C p.E285Q 16
19 COSM10768 TP53 skin,NS,carcinoma,basal cell carcinoma c.535C>T p.H179Y 16
20 COSM10887 TP53 skin,NS,carcinoma,basal cell carcinoma c.833C>G p.P278R 16
21 COSM44241 TP53 skin,NS,carcinoma,basal cell carcinoma c.592G>T p.E198* 16
22 COSM10660 TP53 skin,NS,carcinoma,basal cell carcinoma c.818G>A p.R273H 16
23 COSM44126 TP53 skin,NS,carcinoma,basal cell carcinoma c.507G>A p.M169I 16
24 COSM45751 TP53 skin,NS,carcinoma,basal cell carcinoma c.511G>C p.E171Q 16
25 COSM44130 TP53 skin,NS,carcinoma,basal cell carcinoma c.477C>T p.A159A 16
26 COSM10728 TP53 skin,NS,carcinoma,basal cell carcinoma c.839G>A p.R280K 16
27 COSM43842 TP53 skin,NS,carcinoma,basal cell carcinoma c.770T>C p.L257P 16
28 COSM43695 TP53 skin,NS,carcinoma,basal cell carcinoma c.748C>T p.P250S 16
29 COSM11376 TP53 skin,NS,carcinoma,basal cell carcinoma c.737T>G p.M246R 16
30 COSM10704 TP53 skin,NS,carcinoma,basal cell carcinoma c.844C>T p.R282W 16
31 COSM10939 TP53 skin,NS,carcinoma,basal cell carcinoma c.832C>T p.P278S 16
32 COSM10662 TP53 skin,NS,carcinoma,basal cell carcinoma c.743G>A p.R248Q 16
33 COSM45074 TP53 skin,NS,carcinoma,basal cell carcinoma c.829T>G p.C277G 16
34 COSM10863 TP53 skin,NS,carcinoma,basal cell carcinoma c.833C>T p.P278L 16
35 COSM45739 TP53 skin,NS,carcinoma,basal cell carcinoma c.677G>C p.G226A 16
36 COSM45322 TP53 skin,NS,carcinoma,basal cell carcinoma c.757A>G p.T253A 16
37 COSM44606 TP53 skin,NS,carcinoma,basal cell carcinoma c.665C>T p.P222L 16
38 COSM44295 TP53 skin,NS,carcinoma,basal cell carcinoma c.993+1G>A p.? 16
39 COSM43665 TP53 skin,NS,carcinoma,basal cell carcinoma c.746G>C p.R249T 16
40 COSM45774 TP53 skin,NS,carcinoma,basal cell carcinoma c.899C>G p.P300R 16
41 COSM11449 TP53 skin,NS,carcinoma,basal cell carcinoma c.388C>T p.L130F 16
42 COSM10771 TP53 skin,NS,carcinoma,basal cell carcinoma c.749C>T p.P250L 16
43 COSM44068 TP53 skin,NS,carcinoma,basal cell carcinoma c.532C>A p.H178N 16
44 COSM11152 TP53 skin,NS,carcinoma,basal cell carcinoma c.700T>C p.Y234H 16
45 COSM45834 TP53 skin,NS,carcinoma,basal cell carcinoma c.409C>A p.L137M 16
46 COSM10905 TP53 skin,NS,carcinoma,basal cell carcinoma c.451C>T p.P151S 16
47 COSM6932 TP53 skin,NS,carcinoma,basal cell carcinoma c.733G>A p.G245S 16
48 COSM45424 TP53 skin,NS,carcinoma,basal cell carcinoma c.781A>T p.S261C 16
49 COSM10659 TP53 skin,NS,carcinoma,basal cell carcinoma c.817C>T p.R273C 16
50 COSM10794 TP53 skin,NS,carcinoma,basal cell carcinoma c.796G>A p.G266R 16

Copy number variations for Basal Cell Carcinoma from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 256908 9 98205264 98279247 Mutation PTCH Basal cell carcinoma

Expression for Basal Cell Carcinoma

Search GEO for disease gene expression data for Basal Cell Carcinoma.

Pathways for Basal Cell Carcinoma

Pathways related to Basal Cell Carcinoma according to KEGG:

37
id Name Kegg Source Accession
1 Basal cell carcinoma hsa05217

Pathways related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 19)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 CTNNB1 CYLD GLI1 GLI2 GLI3 HHIP
2
Show member pathways
12.8 GLI1 GLI2 GLI3 PTCH1 PTCH2 SMO
3
Show member pathways
12.55 GLI1 GLI2 GLI3 HHIP PTCH1 SHH
4 12.29 BAX CTNNB1 TP53 WNT16
5
Show member pathways
12.29 PTCH1 PTCH2 SHH SMO WNT16
6 12.24 CTNNB1 PTCH1 SHH SMO TP53 WNT16
7 12.18 CTNNB1 CYLD GLI1 GLI2 PTCH1 PTCH2
8
Show member pathways
12.16 GLI1 GLI3 HHIP PTCH1
9
Show member pathways
12.15 BAX CTNNB1 GLI1 GLI2 GLI3 HHIP
10 12.09 BAX CTNNB1 MMP11 TP53 WNT16
11 12.03 BAX CTNNB1 GLI1 GLI2 GLI3 HHIP
12
Show member pathways
11.92 GLI1 GLI2 GLI3 HHIP PTCH1 PTCH2
13 11.89 BAX CTNNB1 TP53 WNT16
14 11.67 BAX KRT17 TP53
15 11.36 GLI1 GLI2 PTCH1 SHH SMO
16
Show member pathways
11.21 GLI2 HHIP PTCH1 PTCH2 SHH SMO
17 11.16 GLI1 GLI2 SHH
18 10.52 GLI3 SHH
19 10.45 PTCH1 SHH

GO Terms for Basal Cell Carcinoma

Cellular components related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cilium GO:0005929 9.63 GLI1 GLI2 GLI3 PTCH1 SMO SUFU
2 axoneme GO:0005930 9.54 GLI1 GLI2 GLI3
3 cell periphery GO:0071944 9.5 BAX CTNNB1 KRT17
4 ciliary membrane GO:0060170 9.43 HHIP PTCH1 SMO
5 ciliary base GO:0097546 9.26 GLI1 GLI2 GLI3 SUFU
6 ciliary tip GO:0097542 9.1 CYLD GLI1 GLI2 GLI3 SMO SUFU

Biological processes related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 103)
id Name GO ID Score Top Affiliating Genes
1 embryonic digit morphogenesis GO:0042733 9.96 CTNNB1 GLI2 GLI3 SHH
2 determination of left/right symmetry GO:0007368 9.94 SHH SMO SUFU
3 forebrain development GO:0030900 9.94 CTNNB1 GLI3 SHH
4 skin development GO:0043588 9.94 CTNNB1 PTCH2 SHH SUFU
5 negative regulation of cell differentiation GO:0045596 9.93 CTNNB1 GLI3 SHH
6 heart looping GO:0001947 9.93 SHH SMO SUFU
7 vasculogenesis GO:0001570 9.93 CTNNB1 SHH SMO
8 branching involved in ureteric bud morphogenesis GO:0001658 9.93 CTNNB1 GLI3 PTCH1 SHH
9 embryonic limb morphogenesis GO:0030326 9.92 GLI3 PTCH1 SHH
10 positive regulation of neuron apoptotic process GO:0043525 9.92 BAX CTNNB1 TP53
11 limb development GO:0060173 9.91 CTNNB1 GLI3 SHH
12 mammary gland development GO:0030879 9.91 GLI2 GLI3 PTCH1
13 developmental growth GO:0048589 9.9 GLI2 GLI3 SHH SMO
14 T cell differentiation in thymus GO:0033077 9.89 CTNNB1 GLI3 SHH
15 positive regulation of mesenchymal cell proliferation GO:0002053 9.88 CTNNB1 SHH SMO
16 branching morphogenesis of an epithelial tube GO:0048754 9.88 GLI2 GLI3 SHH
17 positive regulation of smoothened signaling pathway GO:0045880 9.88 GLI1 SHH SMO
18 hair follicle morphogenesis GO:0031069 9.88 CTNNB1 KRT17 SHH SMO
19 pattern specification process GO:0007389 9.88 GLI2 GLI3 PTCH1 SHH SMO
20 limb morphogenesis GO:0035108 9.87 BAX GLI3 PTCH1
21 hindbrain development GO:0030902 9.87 CTNNB1 GLI2 SHH
22 proximal/distal pattern formation GO:0009954 9.87 CTNNB1 GLI1 GLI2 GLI3
23 regulation of smoothened signaling pathway GO:0008589 9.86 GLI1 GLI2 PTCH1
24 canonical Wnt signaling pathway GO:0060070 9.86 CTNNB1 GLI1 SHH
25 positive regulation of protein import into nucleus GO:0042307 9.86 GLI3 SHH SMO
26 renal system development GO:0072001 9.86 CTNNB1 PTCH1 SHH SMO
27 anatomical structure formation involved in morphogenesis GO:0048646 9.85 GLI2 GLI3 SHH
28 cell fate determination GO:0001709 9.85 CTNNB1 PTCH1 PTCH2
29 intermediate filament organization GO:0045109 9.85 KRT17 KRT20 SHH
30 cell fate specification GO:0001708 9.85 CTNNB1 SHH SMO
31 positive regulation of neuroblast proliferation GO:0002052 9.85 CTNNB1 GLI3 SHH SMO
32 somite development GO:0061053 9.84 PTCH1 SHH SMO
33 epithelial tube branching involved in lung morphogenesis GO:0060441 9.84 CTNNB1 HHIP SHH
34 spinal cord motor neuron differentiation GO:0021522 9.84 GLI2 GLI3 PTCH1 SHH
35 anatomical structure development GO:0048856 9.83 GLI2 GLI3 SHH
36 embryonic organ development GO:0048568 9.83 GLI3 PALB2 PTCH1 SHH SMO
37 smoothened signaling pathway involved in dorsal/ventral neural tube patterning GO:0060831 9.8 GLI2 GLI3 PTCH1
38 odontogenesis of dentin-containing tooth GO:0042475 9.8 BAX CTNNB1 GLI2 GLI3 SHH SMO
39 digestive tract morphogenesis GO:0048546 9.78 GLI1 SHH
40 positive regulation of protein oligomerization GO:0032461 9.78 BAX TP53
41 thalamus development GO:0021794 9.78 SHH SMO
42 regulation of osteoblast differentiation GO:0045667 9.78 CTNNB1 GLI1
43 ectoderm development GO:0007398 9.78 CTNNB1 SHH
44 cellular response to cholesterol GO:0071397 9.77 PTCH1 SMO
45 mammary gland epithelial cell differentiation GO:0060644 9.77 PTCH1 SMO
46 layer formation in cerebral cortex GO:0021819 9.77 CTNNB1 GLI3
47 keratinocyte proliferation GO:0043616 9.77 PTCH1 WNT16
48 negative thymic T cell selection GO:0045060 9.77 GLI3 SHH
49 replicative senescence GO:0090399 9.77 TP53 WNT16
50 lung-associated mesenchyme development GO:0060484 9.77 CTNNB1 SHH

Molecular functions related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.91 CYLD GLI2 HHIP MMP11 SHH TP53
2 chromatin binding GO:0003682 9.72 CTNNB1 GLI1 GLI2 GLI3 TP53
3 transcription regulatory region DNA binding GO:0044212 9.71 CTNNB1 GLI1 GLI2 TP53
4 hedgehog receptor activity GO:0008158 9.26 PTCH1 PTCH2
5 smoothened binding GO:0005119 9.16 PTCH1 PTCH2
6 patched binding GO:0005113 9.13 PTCH1 SHH SMO
7 hedgehog family protein binding GO:0097108 8.8 HHIP PTCH1 PTCH2
8 protein binding GO:0005515 10.3 BAX CTNNB1 CYLD GLI1 GLI2 GLI3

Sources for Basal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....